Ocular toxoplasmosis therapeutic regimens and prevention of recurrences

Abstract

Ocular toxoplasmosis requires treatment decisions that address both active retinal inflammation and the risk of future lesions. This narrative critical review examines the selection of antimicrobial regimens, the role of adjunctive corticosteroids, and strategies for preventing recurrent retinochoroiditis. Targeted searches of PubMed indexed publications, Cochrane reviews, and original journal reports were conducted in 2026, retaining foundational trials and recent clinical studies. Comparative trials support trimethoprim-sulfamethoxazole as a practical alternative to pyrimethamine-sulfadiazine, while intravitreal clindamycin with dexamethasone offers a local option for selected patients. Evidence does not establish one universally superior regimen for visual recovery. Interpretation is constrained by spontaneous lesion resolution, irreversible damage at presentation, heterogeneous lesion locations, and small trial populations. Intermittent trimethoprim-sulfamethoxazole has stronger randomized evidence for reducing recurrence than acute antimicrobial therapy has for improving long-term visual acuity. Corticosteroid use remains largely guided by clinical judgment and requires effective antiparasitic coverage. Pregnancy, immunosuppression, sulfonamide hypersensitivity, and limited access to monitoring alter the therapeutic balance. Management should combine an assessment of immediate anatomical risk with an individualized prevention plan, recognizing that suppression of recurrence does not demonstrate elimination of tissue cysts or guarantee preservation of vision.